As the legal battle over the abortion pill, mifepristone, unfolds, the U.S. Department of Justice (DOJ) is increasing pressure on the Supreme Court to preserve its availability. New court documents highlight the potential harm to women and healthcare providers if a ban on the medication is enforced, adding a new layer to the ongoing debate.
The controversy stems from a lawsuit filed by a pro-life group in Texas last year, seeking the removal of mifepristone from the market. The group argues that the approval process for the drug by the Food and Drug Administration (FDA) did not adhere. . .